Under pathological conditions, SREBP-1 activation can cause lipid dysfunction to contribute to various metabolic diseases, such as obesity, diabetes mellitus, non-alcoholic fatty liver disease, and cancer (9–12). Here, SREBF1 is linked to cancer.